Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 1 of 49 
  
 
 
 
Protocol Title  
Clinical Evaluation of MucoPEG  for Xerostomia  
 
 Sponsor   
SunBio, Inc.  
95 Sanbon -ro 
Gunpo -si, Gyeonggi -do 
South -Korea  
Protocol Number:   
SB-MU-001   
Version Number :  
1.[ADDRESS_768] will comply with US FDA Regulations, applicable state and local regulations, and 
the Good Clinical Practice guidelines .  
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 2 of 49 
  
PROTOCOL APPROVAL PAGE  
Protocol Title:  Clinical Evaluation of MucoPEG  for Xerostomia  
 
Protocol Number:  SB-MU-001    
 
 
Date:     
  
We the undersigned, have read and approve the clinical investigational plan specified above and 
agree on its content:  
 
 
 
 
 
 
 Kwang  Nho, CEO, SunBio, Inc.    
 
Date  
 
 
 
___________________ ___________________________  
Min-jung Ahn, Director, SunBio, Inc.    
 
 
Date  
 
 
 
______________________________________________  
Yuseung Ha, Strategy & Developi[INVESTIGATOR_1223]. Manager, Rudacure 
Corporation    
 
 
Date  
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_769] read this protocol(s) and agree to conduct and/or supervise the study(ies) in accordance 
with the relevant, current protocol(s); in accordance with accepted good clinical practice 
principles and will only make changes in a protocol after notifying 2TSunBio, Inc . . 
 
I agree to obtaining the written and dated approval/waiver of an Institutional Review Board 
(IRB) prior to initiation of the performance evaluation study and ensure prompt reporting to the 
IRB of any changes in research activity.  
 
I agree  to ensure that all associates, colleagues, and employees assisting in the conduct of the 
study(ies) are informed about their obligations in meeting the above commitments.  
 
I agree to maintain adequate and accurate records and to make those records availab le for 
inspection to both 2TSunBio, Inc.  2T and regulatory bodies.  
 
I agree to disclose to 2TSunBio, Inc. 2Taccurate financial information as required by [CONTACT_1260] 
(21 CFR 54).  
 
I agree to maintain the confidentiality of this study, all study relate d documents and data; and 
will not publish or disclose any content without prior written consent.  
 
The signature [CONTACT_1300] I have read and understand the contents of this protocol 
(or revisions to the protocol) and will adhere to the study protoco l requirements as 
presented including all statements regarding confidentiality, and according to local legal 
and regulatory requirements and applicable U.S. Federal Regulations and Good Clinical 
Practice  guidelines.  
 
 
Investigator Printed Name:    _____________________________________  
 
Investigator Signature:    _____________________________________  
 
Date (dd/mmm/yyyy):    _____________________________________  
 
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_770] Information  
Section 10.3.3 Device/Product Return Procedure  
8.[ADDRESS_771] 
Amendment  
    
    
    
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_772] INFORMATION  ................................ ................................ ................................ ..........................  9 
3 STUDY SYNOPSIS  ................................ ................................ ................................ ................................ ........  10 
4 INTRODUCTION  ................................ ................................ ................................ ................................ ..........  13 
4.1 BACKGROUND AND  RATIONALE  ................................ ................................ ................................ .............................  13 
5 INVESTIGATIONAL DEVI CE DESCRIPTION  ................................ ................................ ................................ .... 13 
5.1 INTENDED USE ................................ ................................ ................................ ................................ ...................  14 
5.2 DOSAGE  ................................ ................................ ................................ ................................ ...........................  14 
5.3 LABELS  ................................ ................................ ................................ ................................ .............................  14 
5.4 COMPARATOR INFORMATION  ................................ ................................ ................................ ...............................  14 
6 STUD Y PURPOSE  ................................ ................................ ................................ ................................ .........  15 
6.1 RISK AND BENEFIT ASSESSMENT  ................................ ................................ ................................ ............................  15 
6.1.1  Risk Minimization  ................................ ................................ ................................ ................................ . 15 
6.1.2  Bene fits ................................ ................................ ................................ ................................ ................  15 
7 STUDY OBJECTIVES AND  ENDPOINTS  ................................ ................................ ................................ ..........  16 
7.1 PRIMARY OBJECTIVE : ................................ ................................ ................................ ................................ ..........  16 
7.2 SECOND ARY OBJECTIVE (S): ................................ ................................ ................................ ................................ .. 16 
7.3 STUDY ENDPOINTS ................................ ................................ ................................ ................................ ..............  16 
8 STUDY DESIGN  ................................ ................................ ................................ ................................ ............  16 
8.1 SCALE ................................ ................................ ................................ ................................ ..............................  17 
8.2 ENROLLMENT  ................................ ................................ ................................ ................................ ....................  17 
8.3 INCLUSION CRITERIA ................................ ................................ ................................ ................................ ...........  17 
8.4 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ...........  18 
8.5 STUDY DURATION ................................ ................................ ................................ ................................ ...............  18 
9 STUDY PROCEDURES  ................................ ................................ ................................ ................................ ... 18 
9.1 STUDY SCHEDULE OF EVENTS  ................................ ................................ ................................ ................................  18 
9.2 VISIT 1 (SCREENING VISIT) ................................ ................................ ................................ ................................ ... 20 
9.3 VISIT 2 (BASELINE VISIT) ................................ ................................ ................................ ................................ ...... 20 
9.4 VISIT 3 ................................ ................................ ................................ ................................ .............................  21 
9.5 VISIT 4 ................................ ................................ ................................ ................................ .............................  23 
9.6 VISIT 5 ................................ ................................ ................................ ................................ .............................  24 
9.7 VISIT 6 ................................ ................................ ................................ ................................ .............................  25 
9.8 VISIT 7 ................................ ................................ ................................ ................................ .............................  26 
9.9 WASHOUT PERIOD  ................................ ................................ ................................ ................................ .............  27 
9.10  PATIENT DIARY ................................ ................................ ................................ ................................ ..................  27 
9.11  INTRA -ORAL PHOTOGRAPH  ................................ ................................ ................................ ................................ .. 27 
9.12  CONCOMITANT MEDICATIONS  ................................ ................................ ................................ ..............................  28 
10 TRAINING, STORAGE AN D ACCOUNTABILITY  ................................ ................................ ..............................  28 
10.1  TRAINING REQUIREMENTS  ................................ ................................ ................................ ................................ ... 28 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 6 of 49 
 10.2  CLINICAL STUDY MATERIALS AND CLINICAL STUDY -SPECIFIC EQUIPMENT  ................................ ................................ ...... 28 
10.3  STUDY DEVICE /PRODUCT TRACEABILITY ................................ ................................ ................................ ..................  28 
10.3.1  Supply of Devices/Products  ................................ ................................ ................................ .............  28 
10.3.2  Device Storage and Accountability  ................................ ................................ ................................ .. 28 
10.3.3  Device/Product Return Procedures  ................................ ................................ ................................ . [ADDRESS_773] (IRB)  ................................ ................................ ................................ ....................  36 
17.2  INFORMED CONSENT PROCESS  ................................ ................................ ................................ ..............................  36 
17.3  PATIENT CONFIDENTIALITY  ................................ ................................ ................................ ................................ ... 36 
18 TERMINATION OF THE CL INICAL INVESTIGATION  ................................ ................................ .......................  37 
18.1  EARLY TERMINATION OF THE CLINICAL INVESTIGATION  ................................ ................................ ..............................  37 
19 DATA MANAGEMENT  ................................ ................................ ................................ ................................ . 37 
19.1  DATA COLLECTION METHODS  ................................ ................................ ................................ ...............................  37 
19.2  COMPLETION OF CASE REPORT FORMS  ................................ ................................ ................................ ...................  37 
19.3  REVIEW AND RETURN OF COMPLETED DOCUMENTATION  ................................ ................................ ...........................  38 
19.4  RETENTION  ................................ ................................ ................................ ................................ .......................  38 
20 INVESTIGATOR/INVESTI GATION SITE SELECTIO N ................................ ................................ ........................  38 
20.1  INVESTIGATOR SELECTION CRITERIA  ................................ ................................ ................................ .......................  38 
20.2  SITE SELECTION CRITERIA  ................................ ................................ ................................ ................................ ..... 38 
21 PUBLICATIONS AND COM MUNICATIONS  ................................ ................................ ................................ .... 39 
21.1  CLINICAL INVESTIGATION REPORT  ................................ ................................ ................................ ..........................  39 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 7 of 49 
 21.2  PUBLICATIONS  ................................ ................................ ................................ ................................ ...................  39 
22 MISCELLANEOUS ................................ ................................ ................................ ................................ .........  39 
22.1  STATEMENT REGARDING THE FUNDING OF THE STUDY  ................................ ................................ ...............................  39 
22.2  CLINICAL INVESTIGATION AGREEMENT  ................................ ................................ ................................ ....................  39 
23 LITERATURE REFERENCE S................................ ................................ ................................ ............................  39 
APPENDIX A: VAS QUES TIONNAIRES  ................................ ................................ ................................ ........  41 
APPENDIX B: DRY MOUTH RELIEF QUESTIONNAIRE  ................................ ................................ ...........  42 
APPENDIX C: DRY MOUT H INVENTORY QUESTION NAIRE  ................................ ................................ .. 43 
APPENDIX D: PPAQ & P PUQ QUESTIONNAIRE  ................................ ................................ ........................  45 
APPENDIX E: THE CHAL LACOMBE SCALE  ................................ ................................ ..............................  49 
 
 
 
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_774] visit  
GCP  Good clinical practice  
ICH International Conference on Harmonization  
IFU Instructions for Use  
ISF Investigator’s site file  
ISO International Organization for Standardization  
PI [INVESTIGATOR_1224]-Product  Use Questionnaire   
SADE  Serious adverse device effect  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Statistical Analysis System software  
SD Standard deviation  
SOP Standard operating procedure  
[LOCATION_003]DE  Unanticipated serious adverse device effect  
VAS  Visual Analog  Scale     
 
 
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_775] Information  
Sponsor:  
 SunBio, Inc.  
95 Sanbon -ro 
Gunpo -si, Gyeonggi -do 
 South Korea  
Tel : +82 -31-423-5467  
Fax : +82 -31-423-5430  
 
CRO:  North American Science Associates I nc. 
[ADDRESS_776] 169 South, Suite 500  
Minneapolis, MN [ZIP_CODE]  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 10 of 49 
 3 STUDY SYNOPSIS  
Study Number  SB-MU-001   
Full Title  Clinical Evaluation of MucoPEG  for Xerostomia  
Short Title  CEMPEG  
Protocol Number  SB-MU-[ADDRESS_777] of MucoPEG™ to that of 
Biotène ® Dry Mouth Gentle Oral Rinse  and  evaluate  its temporal 
change  in a population of patients with  dry mouth symptoms . 
Investigational 
Material /Product  MucoPEG  
Comparative device  Biotène®  Dry Mouth Gentle  Oral Rinse  
Study Objectives  
 Primary Objective:  
To evaluate  the effect of MucoPEG  in relieving xerostomia , 
relative to that of Biotène®  Dry Mouth Gentle Oral Rinse . Effect of 
both products  will be assessed using the Visual Analog ue Scale 
(VAS ) and Dry Mouth Relief Questionnaire.  
Secondary Objective s: 
 To evaluate the effect  of MucoPEG, measured using the Visual 
Analogue Scale, relative to that of Biotene Dry Mouth Gentle 
Oral Rinse after two hours and one week  of use.  
 To compare the effect of MucoPEG  in treating symptoms of 
dry mouth to that of Biotene. Effect will be assessed using  dry 
mouth Product Performance and Attributes Questionnaire 
(PPAQ ) and Post-Product Use Questionnaire (PPUQ)  
 To evaluate the clinical safety of MucoPEG™  
 To examine change  in the symptoms of xerostomia  using the 
Dry Mouth Inventory (DMI)  
 
Study Design  The proposed study will be an open -label randomized cross -over 
design.  
Patients will be randomly assigned  to receive either the 
MucoPEG   or the Biotène®  Dry Mouth Gentle  Oral Rinse  in the 
first period . Patients will use the assigned oral rinse  two times a 
day for two weeks. Patients will switch to the other  treatment after 
a wash -out period  of one week . 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_778] be 18 years of age  or older  
3. Good general and mental health with, in the opi[INVESTIGATOR_1225] , no clinically 
relevant or significant abnormalities found on examination of 
the oral cavity or in their medical history . 
4. Participant  with a Challacombe Scale score of 1 or higher  
5. Participant  agrees not to eat, drink , chew tobacco, chew gum, 
smoke, brush or floss  their teeth  for 2  hours prior to study visits  
6. Participant  agree s not to use any oral care products or any type 
of breath mint or lozenges for 2  hours prior to study  visits  
7. Participant  agrees not to consume any food or liquid during the 
study visits , except for what is provided by [CONTACT_1261] (e.g., water , MucoPEG  and Biotène®  Dry Mouth Gentle  
Oral Rinse  during evaluation periods)  
8. Participant  agrees to using clinical oral care supplies provided 
by [CONTACT_1262]  
9. Understands and is willing  and able to comply with all study 
procedures and restrictions  
 
Exclusion Criteria  1. Women who are pregnant or intending to become pregnant over 
the course of the study , or who have verbally confirmed they 
are pregnant at the Screening Visit  
2. Women who are breast -feeding  
3. Participant is currently undergoing radiotherapy and/or 
chemotherapy .  
4. Any condition the investigator identifies that  may impede  the 
participant's ability to properly participate in the study . For 
example,  Alzheimer's Disease  
5. Participant with untreated oral mucosal disease which in the 
opi[INVESTIGATOR_1226] . For 
example,  presence of  oral ulcerat ion. 
6. Evidence of gross intra -oral neglect or need for extensive dental 
therapy  
7. Denture wearer (complete dentures)   
8. Participant on systemic parasympathetic medications (e.g. 
pi[INVESTIGATOR_1227])  for treating  dry mouth , but the dose requirement of 
which is unstable  
9. Known or suspected intolerance or hypersensitivity to the study 
materials (or closely related compounds) or to any of their 
stated ingredients  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 12 of 49 
 10. Participation in another clinical study (including studies  of 
cosmetic products ) or in receipt of an investigational drug 
within 14 days of the screening visit  
11. Previous participation in this study  
12. Recent history (within one year prior to screening visit ) of 
alcohol or other substance abuse  
Target Population/ 
Sample Size  42 adult s in total for the entire study , males and females  
 
Number of site(s)  Up to 2 sites in the [LOCATION_002]  
Study Duration  Approximately s ix months  
Participant Duration  The study duration for each participant is expected to be 
approximately 42 days.  
Statistical Methods  Descriptive  summaries will be produced for the primary endpoints 
and the secondary endpoints using data from the intent -to-treat 
analysis population.  
 
Hypothesis testing for the primary endpo ints will be carried out 
using data from the intent -to-treat analysis popula tion and, as a 
sensitivity analysis, from the per protocol analysis population. 
Hypothesis tests will be carried out using data on:  
 the difference in the mean change in VAS for dry mouth  
 the difference in the proportion of patients rating the relief 
of dry  mouth as “very good” or “excellent”  in the Dry 
Mouth Relief Questionnaire  (DMRQ) . 
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 13 of 49 
 4 INTRODUCTION  
4.1 Background and Rationale  
Xerostomia is a common oral health problem , affecting  up to 50% of the population (Furness et 
al. 2011). Xerostomia is a subjective feeling  of dryness of the mouth  and can present with or 
without reduced  saliva production  (Furness et al . 2011, Villa et al. 2015 , Jose  et al. 2016) . Dry 
mouth may be associated with  other conditions  such as diabetes and  hypertension . Dry mouth is 
also a common side effect of many different drugs , such as anti -hypertensi ves, anti-depress ants, 
decongestants ( Tan et al. 2018 ). 
 
Mouth dryness is commonly associated with other symptoms such as taste disturbances, bad breath 
and painful mouth ulcers. Dry mouth may also affe ct speech, chewing and swallowing (Dawes 
1987, Furuta et al. 2013 ). 
 
Current management strategies include symptom relieving measures  such as topi[INVESTIGATOR_1228], oral moisturizers, saliva stimulants, and also frequent sips of water. However, the 
evidence in favo ur of any particular topi[INVESTIGATOR_1229]  (Jose  et al.  2016 , Villa et al.2015 ). 
Other products (e.g., Biotène® , Hydris™ ) have became  available for treating dry mouth  in recent 
years,  but there is an increasing demand for more effective dry -mouth relief products.  
 
Polyethylene glycol (PEG) is a polyether compound with low toxicity, and it is used in a variety 
of products ( Sheftel VO 2000). PEG in general is well -known for its moisturizing effect when 
formulated in aqueous liquid, due to its excellent ability to retain water. PEG is a polymer with 
repeating units of ethylene glycol, as depi[INVESTIGATOR_1230] -(CH R2RCH R2RO)n-, where each repeating unit  has 
molecular weight of 44 Da. The repeating unit has one oxygen, it is around this oxygen where 
water molecules bind via hydrogen bond established between the hydrogen of water and the 
oxygen of the PEG. It is known that 2 ~ 3 molecules of water bind to each oxygen of 
PEG.(Antonsen, Kris P. et al. 1992).   
 
SunBio, Inc.  has develop ed MucoPEG™  for the treatment of dry mouth , and is intended to reliev e 
dry mouth symptoms in persons with xerostomia.  
 
The main ingredient of MucoPEG™ is a polyethylene glycol (PEG) derivative. The MucoPEG™ 
PEG derivative also naturally exhibits the hydrophilic characteristic of PEG. Th e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
MucoPEG™ PEG derivative has a m olecular weight of 10,000 daltons (Da). The MucoPEG™ 
PEG derivative has functional groups , which  under aqueous conditions of neutral pH, may assist 
the PEG to stay in contact [CONTACT_1263]. Once in contact [CONTACT_1264], the 
hydrophilic abilit y of PEG , to retain water , helps to moisturize and lubricate the oral mucosa to 
help alleviate oral dryness.  
 
5 INVESTIGATIONAL DEVI CE DESCRIPTION  
 
MucoPEG™ received  FDA clear ance on November 5, 2019 with the 510(k) number K190144. 
MucoPEG™ is an artificial saliva. The main ingredient of MucoPEG™ is a polyethylene glycol 
(PEG) derivative. This PEG derivative forms a covalent bond with the oral epi[INVESTIGATOR_1231]. The 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 14 of 49 
 additives to MucoPEG™ are mint (for flavor) and sodium bicarbonate (for pH maintenance when 
dissolved in water).  
 
MucoPEG™ is available by  [CONTACT_1265]. It is formulated as a powder and 
packaged  in a single -use packet, which should be kept in  a dry environment and stored in the 
freezer between -4 ± 9 Po
PF. The shelf -life is expected to be one year under the prescribed 
environment. MucoPEG™ is not sterile and conforms with ISO [ADDRESS_779] urize/hydrate, clean, soothe oral irritation, and lubricate oral dryness.  
5.2 Dosage  
The content of a single dose containing 1 g powder of MucoPEG™ is dissolved in 20 mL 
(approximately .67 fluid oz) of water using the accessory bottle  and shaken well for about [ADDRESS_780]. Users are recommended not to eat or drink 
for 30 minutes after treatment. MucoPEG™  should be used twice a day, once after breakfast and 
once before bedtime . 
5.3 Labels   
The sponsor will label, package and ship the study materials to the re search facility.  
Each experimental material will be labeled with the following minimum information:  
 
For use in Study S B-MU-001 only  
SunBio, Inc. 
Identifying lot or control number  
Study Material name [CONTACT_1301][INVESTIGATOR_320]:  
“Use as directed”  
Storage conditions as indicated in the IFU  
Contact [CONTACT_1266]  
 
5.4 Comparator Information  
Biotène®  Dry Mouth Gentle  Oral Rinse is specially formulated  to clean, re fresh , and relieve 
dryness and helps soothe oral tissues. Biotène®  Dry Mouth Gentle  Oral Rinse  contains a 
combination of moisturizers and lubricants to provide immediate and long -lasting dry mouth 
symptom relief for up to 4 hours, as measured in a 7 day clinical study.  
The manufacturers suggests using approximately 15 mL (one tablespoon) of Biotène®  Dry 
Mouth Gentle Oral Rinse, ga rgle for 30 seconds and then spa t out. Biotène®  Dry Mouth Gentle 
Oral Rinse can be used as needed up to 2~3 times a day.  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 15 of 49 
 Since  Biotène®  Dry Mo uth Gentle Oral Rinse  is a commercially available product, it will be 
labeled for study use only. Labels will contain  the following information:  
 
For use in Study S B-MU-001 only  
Identifying lot or control number  
Study Material name [CONTACT_1301][INVESTIGATOR_320]:  
“Use as directed”  
Storage conditions as indicated in the IFU  
Contact [CONTACT_1267]  
 
[ADDRESS_781] of using MucoPEG™ and its temporal  
change to those of the Biotène®  Dry Mouth Gentle Oral Rinse  in patients with xerostomia . 
This study will also  gather data on patient reported outcomes on  the safety and performance of the 
product , mouth -feel qualities  and any change s in dry mouth . 
 
6.1 Risk and Benefit Assessment  
6.1.1 Risk Minimization  
There may be unknown risks for patients participating in this study, however efforts to minimize 
risks to study patient s will be made with the following approaches:  
 Conformity with ISO [ZIP_CODE] -1 for cytotoxicity, sens itization, and irritation  
 Selection of an investigator  who is an experienced dental clinician  
 Clearly d efined inclusion and exclusion criteria will be used to ensure only appropriate 
patient s are enrolled  
 Monitoring of investigational sites and patients  
 Review of reported Adverse Events  
Based on the risk assessment report, the side effects of using the experimental device include:   
 Allergic reaction  
 Unpleasantness  
 Foreign -body sensation  
6.1.2 Benefits  
There may be no benefit  to patients participating in this study, however the data collected in this 
study may benefit future patients.   
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 16 of 49 
 7 STUDY OBJECTIVES  AND ENDPOINTS  
7.1 Primary Objective:  
To evaluate  the effect of MucoPEG™  in relieving xerostomia , relative to that of Biotène®  Dry 
Mouth Gentle Oral Rinse . Effect will be assessed using the Visual Analogue Scale (VAS)  and 
Dry Mouth Relief Questionnaire s (DMRQ) . 
7.2 Secondary Objective(s):  
The secondary objectives are  as follows :  
 To evaluate the effect  of MucoPEG, measured using the Visual Analogue Scale, relative to 
that of Biotene Dry Mouth Gentle Oral Rinse after two  hours and one week of use.   
 To compare the effect of MucoPEG  in treating symptoms of dry mouth to that of Biotene. 
Effect will be ass essed using dry mouth P roduct Performance and Attributes Questionnaire 
(PPAQ)  and Post -Product Use Questionnaire (PPUQ)  
 To evaluate the clinical safety  of MucoPEG™  
 To examine change in symptoms of xerostomia using the  Dry Mouth Inventory  (DMI)  
7.[ADDRESS_782] day of a treatment period (on Visit 2 and Visit 5), and after 
the last dose of a product, on the final day of a treatment period (on Visit 4 and 7).  
 
Patients will also be asked to rate  the relief of discomfort of dry mouth using the Dry Mouth 
Relief Questionnaire. The difference in the proportion of patients giving a response of  “4 – Very 
Good” or “5 – Significant/E xcellent”  between MucoPEG   and Biotène®  Dry Mouth Gentle 
Oral Rinse will be examined . 
 
The secondary endpoints include examination of t he temporal change s in the effect of MucoPEG 
relative to Biotene, measured using the Visual Analogue Scale, after using the products for two 
hours (at Visit 2 and Visit 5) and one week  (at Visit 3 and Visit 6).  Other  secondary endpoints  
include assessment of mouth dryness using Product Performance and Attributes Questionnaire 
(PPAQ - 4 parts), and Post-Product Use Questionnaire  (PPUQ) and the Dry Mouth Inventory  
(DMI) . 
Data from these s ources  will be summarised  descriptive ly. 
 
8 STUDY DESIGN  
The study is a randomized, open -labelled crossover trial.  Each patient receives both the 
MucoPEG   and Biotène®  Dry Mouth Gentle Oral Rinse  treatments . 
Patients will be randomly assigned  to one of the two groups. Patients in group A will begin with 
two weeks of treatment (period 1) with MucoPEG , followed by a wash -out period of one w eek, 
and then two weeks of treatment (period 2) with Biotène®  Dry Mouth Gentle Oral Rinse . Patients 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 17 of 49 
 in group B will receive Biotène®  Dry Mouth Gentle Oral Rinse  in period 1 and MucoPEG  in 
period 2.  
8.[ADDRESS_783] signed the informed consent . The 
appropriate Electronic Case Report Form (eCRF) will be completed to document adherence to the 
inclusion and exclusion criteria.  
If a patient fails to meet  the inclusion and exclusion criteria, this will be documented and the ir 
signed consent form and completed record of inclusion/exclusion criteria  will be  retained by [CONTACT_1268]. The patient will not be advanced any further into this clinical investigation . 
When a patient is considered eligible for this  study, the patient will be assigned  an investigational 
number (patient ID number ). This number will be a unique identifier of the patient and documented 
on the eCRF  and all other documentation relating to that patient.  
The Principal Investigator (PI) at each site will maintain a master log that will map each patient 
ID number to the p atient’s name. This log will remain at the study site and will be confidential . 
 
8.[ADDRESS_784] meet all of the inclusion criteria and none of the exclusion crite ria to be eligible 
to participate in the study.  
The inclusion criteria are: 
1. Must have read, understood and signed an informed consent prior to entering the study  
2. Must be 18 years of age  or older  
3. Good general and mental health with, in the opi[INVESTIGATOR_1232], no clinically relevan t or significant abnormalities found on 
examination of the oral cavity or in their medical history  
4. Participant with a Challacombe Scale  score of 1 or higher  
5. Participant agrees not to eat, drink, chew tobacco, chew gum, smoke, brush or floss their 
teeth for 2 hours prior to study visits  
6. Participant agrees not to use any oral care products or any type of breath mint or lozenges 
for 2 hours prior to study visits  
7. Participant agrees not to consume any food or liquid during the study visits, except for 
what is provided by [CONTACT_1269] (e.g., water , MucoPEG and Biotène®  Dry 
Mouth Gentle  Oral Rinse  during evaluation periods)  
8. Participant agrees to using clin ical oral care supplies provided by [CONTACT_1270]  
9. Understands and is willing  and able to comply with all study procedures and restrictions  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 18 of 49 
 8.4 Exclusion Criteria  
If a patient meets the ex clusion criteria, s/he will not be able to participate in the study.  
The exclusion criteria are:  
1. Women who are pregnant or intending to become pregnant over the course of the study, 
or who have verbally agreed that they are pregnant  at the Screening Visit  
2. Women who are breast -feeding  
3. Participant is currently undergoing radiotherapy and/or chemotherapy.  
4. Any condition the investigator identifies that  may impede the participant's ability to 
properly participate in the study. For example, Alzheimer's Disease  
5. Participant with untreated oral mucosal disease which in the opi[INVESTIGATOR_1233]. For example,  presence of oral ulceration.  
6. Evidence of gross intra -oral neglect or need for extensive dental therapy  
7. Denture wearer (com plete dentures)   
8. Participant on systemic parasympathetic medications (e.g. pi[INVESTIGATOR_1227])  for treating dry 
mouth, but the dose requirement of which is unstable  
9. Known or suspected intolerance or hypersensitivity to the study materials (or closely 
related comp ounds) or to any of their stated ingredients  
10. Participation in another clinical study (including studies of cosmetic products) or in 
receipt of an investigational drug within 14 days of the screening visit  
11. Previous participation in this study  
12. Recent history  (within  one year prior to screening visit) of alcohol or other substance 
abuse  
 
8.[ADDRESS_785] around six months and each patient’s participati on is 
expected to last around 42  days. Each patient ’s involvement in the study will last approximately 
3 to 5 hours per study visit with a  total time commitment expected to be  around 30 hours for 
each patient.  
9 STUDY  PROCEDURE S 
9.1 Study Schedule of Events  
Table 1 on the next page consists of the scheduled assessments for each study visit.  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 19 of 49 
 Table 1: Schedule of Events  
 
 First Treatment  
2 times a day for 2 weeks   Second Treatment  
2 times a day for 2 weeks  
Assessment  Visit 1  
 Wash -
out 
period * 
(7 Days ) Visit 2  
(Day 1  +  
2 Days ) Visit 3  
(Day 7  ±  
2 Days ) Visit 4  
(Day 14  ±  
2 Days ) Wash -out 
period * 
(7 Days ) Visit 5  
(Day 22  + 
2 Days ) Visit 6  
(Day 28  ± 
2 Days ) Visit 7  
(Day 35  ±  
2 Days ) 
Informed Consent  X         
Inclusion/Exclusion  X         
Demographic s/Medical 
History  X         
VAS  Measurements    X X X  X X X 
Dry Mouth Relief 
Questionnaire    X X X  X X X 
Oral Tissue Exam using 
theChallacombe Scale Score  X  X X X  X X X 
Dry Mouth Inventory    X X X  X X X 
Patient Diary    X X X  X X X 
Intra -Oral Photo  **   X X X  X X X 
PPAQ1    X X X   X X X 
PPAQ2    X X X  X X X 
PPAQ3    X X X  X X X 
PPAQ4     X X   X X 
PPUQ      X    X 
Concomitant medication  X  X X X  X X X 
Adverse Events    X X X  X X X 
* Patients must undergo a washout period of at least 7 days prior to using either treatment  
**Patients that opt in/consent to having a pi[INVESTIGATOR_1234] . Photo must be taken as a pre -use measurement . 
For details of the Study Questionnaires , see Appendix  A, B, C, D  and E . 
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 20 of 49 
 9.2 Visit 1  (Screening Visit)  
Patients interested in participating the study will be consented and enrolled at Visit 1. Patients 
will be consented prior to  conducting any study assessments.  
 
The following will be completed at Visit 1:  
 
 Obtain Informed Consent from t he patient  
 Verify Inclusion  criteria has been met and no Exclusion Criteria  has been met  
 Collect Demographics  
 Collect Medical History  
 Collect  Concomitant Medications  
 Conduct the Oral  Tissue Exam using the Challacombe Scale Score  
 Schedul e patient for future study visits  
To ensure an effective washout period, the study product  will not  be provided to the patient during 
Visit 1 to avoid the patient  starting the treatment  before obtaining baseline data at Visit 2  (Baseline 
Visit) . Patients sh ould be reminded to not to use any oral rinse products during the washout 
period, as described in  Section 9.9. 
9.3 Visit 2 (Baseline Visit)  
The second visit will be the Baseline Visit and should occur 1 (+2) days after screening visit and 
could last up to  [ADDRESS_786]-use information  at multiple timepoints  
(5 min, 30 min, 60 min, 120 min, and 240 min) . 
 
Before starting any  treatment , the following Upre-use measurements U must be assessed  by [CONTACT_1271] U: 
 
 Visual Analog ue Scale (VAS)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra-Oral Photo  
Before starting any treatment , the following Upre-use measurement U must be completed by [CONTACT_1272] U: 
 
 Dry Mouth Inventory (DMI)  
Patients will not be allowed to eat or drink during the study visit except for when directed 
by [CONTACT_464].   
 
Once the VAS, DMI , the Oral Tissue Exam and Intra-Oral photo have been completed,  the sealed 
envelope will be opened, and treatment order noted. The p atient  will then self-administer the  first 
dose of the treatment into their mouth using the first sample assigned based on the randomization 
card.  
 
The Upost-use measurements U will include the following  at the appropriate timepoints : 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 21 of 49 
  5 (+ 5) minutes after [ADDRESS_787]
P dose: PP AQ1 (Questions 1 -3; completed while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_788]
P dose:  PPAQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_789]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
 120 (± 10) minutes after [ADDRESS_790]
P dose: VAS, Dry Mouth Relief Questionnaire  (DMRQ) , and 
PPAQ3 (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_791]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic or completed at home)  
 
Other Assessments /Schedule of Events  that must be completed during Visit 2 include:  
 Provide the patient with a patient diary and instructions as indicated below  
 Review any changes in concomitant medications  
 Review any side effects/adverse events  
 Provide the patient with in structions to use the product at home  
 Schedule the next follow -up visit  (Visit 3) and instruct patients NOT to take the product 
the morning  of Visit [ADDRESS_792] (i.e. was the MucoPEG   stored in the freezer as indicated 
and was the Biotene stored at room temperature as indicated), the hours of use, and any side 
effects and/or adverse events they experience while using their assigned study product . Patients 
will be asked anopen question in their diary about how their mouth feels after using the product.  
 
Patients  will be instructed to call the clinic if they experience any adverse side effects and/or 
adverse events.  
 
Patient s will be instructed to use the product at home for [ADDRESS_793]  visit should occur 7 (± 2)  days after the baseline visit  and could  last up to  [ADDRESS_794] -use information at multiple timepoints (5 min, 30 min, 60 min, 120 
min, 240 min).  
 
Before starting any treatment , the following Upre-use measurements U must be assessed by [CONTACT_1273] U: 
 
 Visual Analogue Scale (VAS)  
 Dry Mouth Relief Questionnaire (DMRQ)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra -Oral Photo  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_795] be completed by [CONTACT_1274] U: 
 
 PPAQ4 (Questions 15 -23; completed while patient is in clinic)  
 Dry Mouth Inventory (DMI)  
Patient s will not be allowed to eat or drink during the study visit except for when directed 
by [CONTACT_464].  
 
The patient  will then self -administer the first dose of the treatment into their mouth using the first 
sample assigned based on the randomization card.  
 
The Upost-use measurements U will include the following at the appropriate timepoints : 
 5 (+ 5) minutes after [ADDRESS_796]
P dose: PP AQ1 (Questions 1 -3; completed  while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_797]
P dose:PP AQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_798]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
 120 (± 10) minutes after [ADDRESS_799]
P dose: VAS, Dry Mouth Relief Questionnaire  (DMRQ) , and 
PPAQ3 (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_800]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in  
clinic  or completed at home)  
 
Other Assessments/Schedule of Events that must be completed during V isit 3  include:  
 Provide the patient with a patient diary and instructions as indicated below  
 Review any changes in concomitant medications  
 Review any side effects/adverse events  
 Provide the pati ent with instructions to use the product at home  
 Schedule the next follow -up visit (Visit 4) and instruct patients NOT to take the product 
the morning of Visit [ADDRESS_801] (i.e. was the MucoPEG   stored in the freezer as indicated 
and was the Biotene stored at room temperature as indicated), the hours of use, and any side 
effects and/or adverse events they experience while using their assigned study product . Patients 
will be asked a general question in their diary about how their mouth feels after usi ng the product.  
 
Patients  will be instructed to call the clinic if they experience any adverse side effects and/or 
adverse events.  
 
Patients will be instructed to use the product at home for [ADDRESS_802] 
container and patient diary.  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 23 of 49 
 9.5 Visit 4  
The fourth visit should occur 14 (± 2) days after the baseline visit and could  last up to  [ADDRESS_803] -use information at multiple timepoints (5 min, 30 min, 60 
min, 120 min , 240 min).  
 
Before starting any treatment , the following Upre-use measurements U must be assessed by [CONTACT_1271] U: 
 
 Visual Analogue Scale (VAS)  
 Dry Mouth Relief Questionnaire (DMRQ)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra -Oral Photo  
Before starting any treatment , the following Upre-use measurement U must be completed by [CONTACT_1274] U: 
 
 PPAQ4 (Questions 15 -23; completed while patient is in clinic)  
 Dry Mouth Inventory (DMI)  
Patients will not be allowed to eat or drink during the study visit except for when directed 
by [CONTACT_464].  
 
The patient will then self -administer the first dose of the treatment into their mouth using the first 
sample assigned based on the randomization card.  
 
The Upost-use measurements U will include the following at the appropriate timepoints : 
 5 (+ 5) minutes after [ADDRESS_804]
P dose: PP AQ1 (Questions 1 -3; completed while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_805]
P dose:PP AQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_806]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
 120 (± 10) minutes after [ADDRESS_807]
P dose: VAS, Dry Mouth Relief Questionnaire  (DMRQ) , and 
PPAQ3 (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_808]
P dose: PP AQ3 (Questions 12 -14) and PPUQ  (completed while 
patient is in clinic ) 
 
Other Assessments/Schedule of Events that must be completed during V isit 4  include:  
 Collect the patient diary from the patient  
 Review any changes in concomitant medications  
 Review any side effects/adverse events  
 Schedule t he next follow -up visit (Visit 5 ) and instruct patients NOT to u se any product as 
indicated in the Washout Period  
 
After all assessments are completed for Visit 4, the first treatment phase will be considered 
complete and patient s will be instructed to follow the one-week wash -out period , as described in 
Section 9.9. 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 24 of 49 
  
9.6 Visit 5  
The fifth visit should occur 22 ( + 2) days after the baseline visit and could  last up to  [ADDRESS_809] -use information at multiple timepoints (5 min, 30 min, 60 min, 
120 min , 240 min).  
 
Before starting any treatment , the following Upre-use measurements U must be assessed by [CONTACT_1271] U: 
 
 Visual Analogue Scale (VAS)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra -Oral Photo  
Before starting any treatment , the following Upre-use measurement U must be completed by [CONTACT_1272] U: 
 
 Dry Mouth Inventory (DMI)  
Patients will not be allowed to eat or drink during the study visit except for when directed 
by [CONTACT_464].   
 
Once the VAS, DMI , the Oral Tissue Exam and Intra -oral photo have been completed,  the patient 
will then self-administer the first dose of the treatment into their mouth using the second sample 
assigned. If the patient’s randomized first sample was the MucoPEG  then the second sample 
assigned to the patient should be the Biotène®  Dry Mouth Gentle Oral Rinse and vice versa.  
 
The Upost-use measurements U will include the following at the appropriate timepoints : 
 5 (+ 5) minutes after [ADDRESS_810]
P dose: PP AQ1 (Questions 1 -3; completed while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_811]
P dose:  PPAQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_812]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
 120 (± 10) minutes after [ADDRESS_813]
P dose: VAS, Dry Mouth Relief Questionnaire  (DMRQ) , and 
PPAQ3  (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_814]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic or completed at home)  
 
Other Assessments/Schedule of Events that must be completed during Visit 5 include:  
 Provide the patient with a patient diary and instructions as indicated  below  
 Review any changes in concomitant medications  
 Review any side effects/adverse events  
 Provide the patient with instructions to use the product at home  
 Schedule the next follow -up visit (Visit 6) and instruct patients NOT to take the product 
the morni ng of Visit 6  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_815] (i.e. was the MucoPEG   stored in the freezer as indicated 
and was the Biotene stored at room temperature as indicated), the hours of use, and any side 
effects and/or adverse events they experience while using their assigned study product . Patients 
will be asked a general question in their diary about how their mouth feels after using the product.  
 
Patients  will be instructed to call the clinic if they experience any adverse side effects and/or 
adverse events.  
 
Patients will be instructe d to use the product at home for [ADDRESS_816] 
container and patient diary.  
9.7 Visit 6  
The sixth  visit should occur 28 (± 2) days after  the baseline visit and could  last up to  [ADDRESS_817] -use information at multiple timepoints (5 min, 30 min, 60 min, 120 
min, 240 min).  
 
Before starting any treatment , the following Upre-use measurements U must be assessed by [CONTACT_1271] U: 
 
 Visual Analogue Scale (VAS)  
 Dry Mouth Relief Questionnaire (DMRQ)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra -Oral Photo  
Before starting any treatment , the following Upre-use measurement U must be completed by [CONTACT_1274] U: 
 
 PPAQ4 (Questions 15 -23; completed while patient is in clinic)  
 Dry Mouth Inventory (DMI)  
Patients will not be allowed to eat or drink during the study visit except for when directed 
by [CONTACT_464].  
 
The patient will then self -administer the first dose of the treatment into their mouth using the  
second  sample assig ned.  
 
The Upost-use measurements U will include the following at the appropriate timepoints : 
 5 (+ 5) minutes after [ADDRESS_818]
P dose: PP AQ1 (Questions 1 -3; completed while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_819]
P dose:PP AQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_820]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 26 of 49 
  120 (± 10) minutes after  [ADDRESS_821]
P dose: VAS, Dry Mouth Relief Questionnaire (DMRQ) , and 
PPAQ3 (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_822]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic or completed at home)  
 
Other Assessments/Schedule of Events that must be completed during Visit 6 include:  
 Provide the patient with a patient diary and instructions as indicated below  
 Review any changes in concomitant medications  
 Review any side effects/adverse events  
 Provide the pati ent with instructions to use the product at home  
 Schedule the next follow -up visit (Visit 7) and instruct patients NOT to take the product 
the morning of Visit [ADDRESS_823] (i.e. was the MucoPEG   stored in the freezer as indicated 
and was the Biotene stored at room temperature a s indicated), the hours of use, and any side 
effects and/or adverse events they experience while using their assigned study product . Patients 
will be asked a general question in their diary about how their mouth feels after using the product.  
 
Patients  will be instructed to call the clinic if they experience any adverse side effects and/or 
adverse events.  
 
Patients will be instructed to use the product at home for [ADDRESS_824] 
container and patient diary.  
9.8 Visit 7  
The seventh  visit should occur 35 (± 2) days after the baseline visit and could  last up to  [ADDRESS_825] -use information at multiple timepoints (5 min, 30 min, 60 
min, 120 min , 240 min).  
 
Before starting any treatment , the following Upre-use measurements U must be assessed by [CONTACT_1271] U: 
 
 Visual Analogue Scale (VAS)  
 Dry Mouth Relief Questionnaire (DMRQ)  
 Oral Tissue Exam using the Challacombe Scale Score  
 Intra -Oral Photo  
Before starting any treatment , the following Upre-use measurement U must be completed by [CONTACT_1274] U: 
 
 PPAQ4 (Questions 15 -23; completed while patient is in clinic)  
 Dry Mouth Inventory (DMI)  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_826]-use me asurements U will include the following at the appropriate timepoints : 
 5 (+ 5) minutes after [ADDRESS_827]
P dose: PP AQ1 (Questions 1 -3; completed while patient is in clinic)  
 30 (± 10) minutes after [ADDRESS_828]
P dose:PP AQ2 (Questions 1 -11; completed while patient is in 
clinic)  
 60 (± 10) minutes after [ADDRESS_829]
P dose: PP AQ3 (Questions 12 -14; completed while patient is in 
clinic)  
 120 (± 10) minutes after [ADDRESS_830]
P dose: VAS, Dry Mouth Relief Questionnaire  (DMRQ) , and 
PPAQ3 (Questions 12 -14; completed while patient is in clinic)  
 240 (± 10) minutes after [ADDRESS_831]
P dose: PP AQ3 (Questions 12 -14); and PPUQ ( completed while 
patient is in clinic ) 
 
Other Assessments/Schedule of Events that must be completed during Visit 7 include:  
 Collect the patient diary from the patient  
 Review any changes  in concomitant medications  
 Review any side effects/adverse events and resolve if appropriate  
 
After all assessments are completed for Visit 7, the second  treatment phase will be considered 
complete  and the subject’s participation in the study will be complete.  
9.[ADDRESS_832] until the baseline visit (Visit 2). 
The second washout period will start after the end of Visit [ADDRESS_833] (i.e. was the MucoPEG   stored in the freezer as indicated and was the Biotene  stored 
at room temperature , as indicated), the hours of use, and any side effects and/or adverse events 
they experience while using their assigned study product. Patients will also be asked a n open  
question about how their mouth feels after using the product.   
9.[ADDRESS_834] to the 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 28 of 49 
 patient. A total of 5 pi[INVESTIGATOR_1235]: 1)  upper side – hard plate 2) tongue 3) 
buccal mucosa: right side 4) buccal mucosa: left side 5) floor of mouth. Intra-oral photographs 
will be taken at the designated visits a s described in Table 1. 
9.12 Concomitant Medications  
Concomitant medications are prescription medications, over -the-counter (OTC) drugs or dietary 
supplements taken by a patient. Concomitant medications should be collected at Visit [ADDRESS_835] y mouth.  
 
10 TRAINING, STORAGE AN D ACCOUNTABILITY  
10.1 Training Requirements  
Prior to investigation site activation or subsequent involvement in clinical study activities, the 
Sponsor  or designated CRO will provide clinical study training relevant and pertinent to  the 
involvement of personnel conducting clinical study activities.  
10.2 Clinical Study Materials and Clinical Study -Specific Equipment  
The sponsor or designated CRO will provide study documentation (e.g. Investigator Site File, 
eCRF access, Study Worksheets, etc.) and study devices to the site personnel.  
The site personnel are responsible to send an acknowledgment of receipt to the sponsor or 
designee after receiving the study devices (via email or fax).  
Where applicable, computer and i nternet access may be a pre-requisite for site participation.  
10.3 Study Device/Product Traceability  
10.3.1  Supply of Devices/ Products  
The study sponsor will have the product shipped directly to the investigational site.  
10.3.[ADDRESS_836] be performed as soon as the device/product is received by [CONTACT_1275]/investigation site. Devices/products rece ived by [CONTACT_1276][INVESTIGATOR_1236]. The MucoP EG PTM
P provided by [CONTACT_1277], batch numbers, or serial numbers to each 
device/product.  
All information for the use, storage and handling of the investigational device/product as 
indicated in the Instructions for U se must be taken into account.  
10.3.3  Device/ Product Return Procedures  
The vendor of products manufactured by [CONTACT_1278]., will collect the returned and any 
malfunction device /product . 
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 29 of 49 
 11 PATIENT  ACCOUNTABILITY AND WITHDRAWAL  
11.1 Patient  Withdrawals and Discontinuation  
During this study , patient s may choose to discontinue / leave the study for any of the following 
reasons:  
 Patient ’s withdrawal of consent.   
 Any unexpected adverse effect which, in the opi[INVESTIGATOR_1237], is related 
to the device and will endanger the well being of the patient  if the treatment is continued.  
 The deterioration of any underlying illness(es), infection or condition(s) that might interfere 
with the Clinical Investigation Plan.  
 Any problem deemed by [CONTACT_079] [INVESTIGATOR_1238]/  SunBio, Inc.  to be sufficient to cause 
discontinuation.   
 
Patients who are withdrawn from the study because of an unexpected adverse event will be treated 
until its  resolu tion. The Principal Investigator [INVESTIGATOR_1239](s) for 
patient  withdr awal in his/her eCase Report Form (eCRF) or EDC system and the monitor must be 
notified.  
Patient s have the right to withdraw from the study at any time and for any reason without prejudice 
to their future medical care. If a patient  decides to withdraw, al l study tests and procedures will be 
stopped and the cause of withdrawal  will be documented . The investigative site must account for 
and document all patient s enrolled in the study, including those withdrawn from the study or lost 
to follow -up. If a patien t withdraws from the clinical investigation, the reason(s) shall be reported 
on the eCRF.  
 
Additional study data may no longer be collected after a patient’s withdrawal . Data collected up 
to the point of withdrawal  will be used for analysis. Patient s who are withdrawn will not be 
replaced if they have received any of MucoPEG  or Biotène®  Dry Mouth Gentle Oral Rinse 
doses . Patient s will be replaced if they are withdrawn prior to receiving the first dose on Visit [ADDRESS_837] the patient  (or 
their legally authorized representative) by [CONTACT_756] , and if not successful, a certified letter sent to 
the patient ’s last known address. All contact [CONTACT_1279] -up information must be 
documented in both the patient ’s medical records and on the eCRFs .  
[ADDRESS_838] of the study, in any phase of 
the study or after the study is completed.  An adverse event ca n be identified by [CONTACT_1280] .  
 
Note: The Federal Privacy Rule (HIPAA) specifically permits the use and disclosure of protected 
health information “without written authorization of the individual” when used for public health 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_839] -market surveillance [45 CFR 164.512]. This use and 
disclosure is patient  to the minimum necessary standard, i.e. “the minimum necessary to 
accomplish the intended use, disclosure, or request” [45 CFR 164.502].  
12.[ADDRESS_840] has exited/withdrawn from the study. Only 
treatment -emergent adverse event will be collected and reported.  
 
Examples of anticipated adverse events are:  
• Temporary and mild, mouth or tongue sensations such as:  
o Numbness  
o Burning sensation  
o Tingling sensations  
o Taste alteration  
 
The following are definitions related to safety:  
 
Adverse event (AE)  means any undesirable clinical occurrence in a patient , whether or not it is 
considered to be device - or drug -related .  
 
Device -related adverse event  (i.e., adverse device effect) is an AE considered by [CONTACT_1281] a reasonable likelihood of being associated with the experimental device  or device under 
study .  
 
Serious adverse event  is an adverse event or suspected adverse reaction which, in the view of 
either the investigator or sponsor, results in any of the following outcomes: Death, a threat to life , 
inpatient hospi[INVESTIGATOR_1081], a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital 
anomaly/birth defect. Important medical  events that may not result in death, be life - threatening, 
or require hospi[INVESTIGATOR_708], based upon appropriate medical 
judgment, they may expose the patient to an increased risk of such outcomes  and may require 
medical or sur gical intervention to prevent one of the outcomes listed in this definition.  
 
Serious adverse device effect  is a device effect that has a serious adverse effect on the health or 
safety of study participants , causing hospi[INVESTIGATOR_059] , or is life threatenin g or causes death.  
 
Unanticipated adverse device effect  is any serious adverse device effect on the health or safety  
of study participants  or any life -threatening problem or death , that is  caused by [CONTACT_1282] 
a device . That effect, problem or death and its nature, severity or degree of incidence was not 
previously identified in the investigational plan or application . This also included  any other 
unanticipated serious problem which may be associated with a device  and is relate d to the rights, 
safety and welfare of patient s.  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_841] s/adverse events  to the Sponsor  
using the appropriate eCRF in the EDC system . If the Investigator is not able to report the  adverse 
event or adverse device effect through the EDC system, the Investigator must notify the site 
monitor or Clinical Study Manager. If the adverse device effect /adverse event  is considered by [CONTACT_1283]/or unanticipated, the In vestigator must report it to the IRB as soon 
as possible and within IRB requirements.  
 
A serious AE involving the comparative device is reported to the study monitor and IRB.   
 
12.4 Follow -up of Unresolved Events  
All serious adverse events, serious adverse device effects and/or unexpected adverse device effects 
will be followed up until: 
 Thirty days after the onset of the event  
 Resolution of the event  
 Reaching a stable condition if its effect is a permanent impairment  
 The end of a patient’s participation in the study  
 
13 CLINICAL SITE MONITO RING  
Clinical site monitoring is conducted to ensure that the study is implemented in accordance  
to the protocol and/or other operating procedures, and that the quality and integrity of  study  
data and data collection methods are maintained. The monitor will evaluate study processes and 
documentation based on the Good Clinical Practice guidelines (GCP). Clinical Monitoring for this 
study may be performed with a combination of on-site visits and remote  sessions . Site monitoring 
will be conducted under the direction of a separate Clinical Monitoring Plan.  
 
The monitor will be responsible for securing the compliance of the Principal Investigators to the 
signed agreement, the Clinical Study P rotocol, Good Clinical Practice guidelines (GCP), or 
conditions of approval imposed by [CONTACT_1284].   
 
The Principal investigator [INVESTIGATOR_1240] a representative from SunBio , Inc. to inspect all eCase 
Report Forms and corresponding portions of the patient ’s clinic records and/or original hospi[INVESTIGATOR_1241], either on -site or remotely, at regular intervals throughout the clinical investigation.  
These inspections are for the purpose of verifyi ng adherence to the Clinical Study Protocol and 
the completeness and accuracy of the data being entered on the eCase Report Forms.  
The extent of source data verification is detailed in the monitoring plan. Source data is defined as 
all the information in the original records, certified copi[INVESTIGATOR_1242], observations, or other activities in a clinical investigation, necessary for the 
reconstruction and evaluation of the clinical investigation. Source document are defined a s printed, 
optical or electronic document containing source data, e.g. Hospi[INVESTIGATOR_1097], laboratory notes, 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 32 of 49 
 device accountability records, photographic negatives, radiographs, records kept at the 
investigation site, at the laboratories and at the medico -technical departments involved in the 
clinical investigation.  
A Principal Investigator [INVESTIGATOR_1243]/or written notification of the deficiency, which will include a request that deviation 
be corrected immediately.  If the corrections are not made, shipment of products to the institution 
will be suspended.  A request  will be made to the Principal I nvestigator that any products still in 
his/her possession are returned to SunBio , Inc.   
 
Monitor ing for this study will be performed by [CONTACT_1285] .  
 
[ADDRESS_842] of the study at their site(s).  The 
investigator will ensure that the study is conducted in compliance with GCP, the protocol, the 
Clinical Study Agreement,  and applicable regulations in [ADDRESS_843] of the study, including assurance that 
the study meets the FDA regulations and other regulatory requirements as applicable.   
The sponsor’s study -related duties and functions may be transferred to a Contract  Research  
Organization (CRO).  
14.3 Auditing  
During the running of the clinical investigation, SunBio, Inc.  may appoint Quality Assurance 
(QA) personnel to provide audit of the administration and conduct of the clinical investigation, 
both at the investigation site and at SunBio, Inc. .  
The relevant Regulatory Authority also has the right to conduct an audit of the clinical 
investigation, that the clinical investigations were, in fact, performed at stated investigation sites 
and that the data reported to the authority in support of a mark eting application accurately 
reflects the data in the records of the Principal Investigator.  The authority also inspects such 
studies to verify that the clinical investigations were conducted in accordance with Government 
regulations relating to the Institutional Review Board  and Informed Consent.  It is the joint 
responsibility of the Sponsor and the Principal Investigator [INVESTIGATOR_1244].  
In the event the regulatory authority  desires to inspect this clinical investigation, the Principal 
Investigator [INVESTIGATOR_1245] m the audit in a timely fashion.  
14.4 Prot ocol Deviations  
A protocol deviation is failure to comply with the requirements specified within the clinical 
study protocol, ICH GCP, Manual of Operations or IRB requirements. Investigators are not 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_844] patient ’s 
rights and well -being, or the scientific integrity of the study (ISO [ZIP_CODE]). The noncompliance 
may be on the part of the patient , the investigator, or study staff. As a result of deviations, 
corrective actions are to b e developed by [CONTACT_1286].  
 
All deviations from the protocol must be addressed in study source documents and  promptly 
reported to SunBio , Inc., or the designated CRO  and the local IRB/IEC, according to their 
requirements. The site PI/study staff is responsible for knowing and adhering to their IRB 
requirements.  
 
In the event  that a procedural  variation  occurs, the SunBio , Inc. should  be notified  
immediately  to discuss  the required  follow -up. Protocol  deviations  or violations  must  be 
documented  on the appropriate  case report form after discussion  with the study  monitor.  
 
Data  must  not be invalidated,  eliminated  or discarded  by [CONTACT_779]. All results  must  be 
accounted for  study  source  documents.   
14.5 Changes to Protocol  
In the event the study protocol is amended, the sponsor  will provide the Principal Investigator 
[INVESTIGATOR_1246](s) and a revised protocol. I t is the responsibility of the  
Principal Investigator [INVESTIGATOR_1247](s) should be submitted for  
IRB approval.  
 
Protocol amendments that affect the patient  rights, safety, or welfare must be submitted  
to the IRB  for approval . The Sponsor must be notified of the approval, in  writing, prior  
to implementation.  
14.[ADDRESS_845] of  
disposition.  
 
15 STATISTICAL CONSIDER ATIONS  
15.1 Sample Size Determination  
The primary endpoint is the difference between MucoPEG   and Biotène®  Dry Mouth Gentle 
Oral Rinse in the reduction of mouth dryness , assessed using the Visual Analogue  Scale (VAS),  
for each  patient afte r using each product for two weeks . 
  
The hypotheses are as follows:  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 34 of 49 
 Null hypothesis:  
Change in VAS after MucoPEG   minus  change in VAS after Biotène®  Dry Mouth Gentle Oral 
Rinse  ≤ 0 
Alternative hypothesis:  
Change in VAS after MucoPEG   minus  change in VAS after Biotène®  Dry Mouth Gentle Oral 
Rinse  > [ADDRESS_846] deviation of 1.50 and a Type I err or of 0.05, an effective sample size of 38 patient s will 
provide 80% power to reject the null hypothesis of no difference between the two devices 
(MucoPEG   vs Biotène®  Dry Mouth Gentle Oral Rinse ). 
 
For comparing the percentage of patients giving a response of “ Very Good” or “ Significant / 
Excellent” in the Dry Mouth Relief Questionnaire  (DMRQ) , an effective sample size of 32 
patient s will provide 80% power to demonstrate theeffect of MucoPEG  is greater than  
Biotène®  Dry Mouth Gentle Oral Rinse . We assumed a  difference in percentages of 0.[ADDRESS_847] deviation of 0.45 and a Type I error rate of 0.05.  
 
Since the effective sample size for the VAS scale analysis is greater than that of the Dry Mouth 
Relief Questionnaire analysis, and effective sa mple size of 38 patient s will be used.  Assuming a 
10% loss to follow -up, total enrollment for this study is appr oximately 42 patient s. 
15.2 Randomization   
Patients will be randomly allocated to either group A or group B in this crossover study in a 1:1 
ratio. Patients in group A will begin using MucoPEG   from Visit 2 for two weeks (period 1). 
This is followed by a washout period of one week. They will switch to using Biotène®  Dry Mouth 
Gentle Oral Rinse  from  Visit 5 for another two weeks (period 2). Patients in group B will follow 
the same pattern except they receive Biotène®  Dry Mouth Gentle Oral Rinse  in period 1 and 
MucoPEG   in period 2.  
 
Because of differences in the package of the two products, blinding of treatment allocation in 
patients is not possible. Study assessors administrating the questionnaires, data entry staff and the 
statistician may be blinded to the product used at each period.  
 
15.3 Statistical Methods  
Data will be summari sed descriptively as tables and /or graphs. Continuous variables such as 
patient’s assessment of mouth dryness using the Visual Analogue Scale (VAS) are to be 
summarised as mean, standard deviation, number of non -missing observations,  median, 
minimum and maximum by [CONTACT_1287] ( MucoPEG  or Biotène®  Dry Mouth Gentle Oral 
Rinse ) and period (1 – before washout or 2 – after washout). Discrete variables such as ordinal 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 35 of 49 
 responses or binary responses (yes or no) from the Dry Mouth Relief Questionnaire, the Product 
Performance and Attributes Que stionnaire, etc. are to be summarised as frequency counts and 
percentages by [CONTACT_1288].  
 
Measurements of symptom severity will be tested in a Student’s t test for the difference between 
MucoPEG  and Biotène®  Dry Mouth Gentle Oral Rinse  in their me an changes in Visual 
Analogue Scale for each treatment period.  Changes between Visit 2 and Visit 4 and between 
Visit 5 and 7 will be tested for the primary endpoint and changes between Visit 2 and Visit 3, 
between Visit 5 and Visit 6, within Visit 2 (befor e the first dose and two hours after the first 
dose) and Visit 5 (before the first dose and two hours after the first dose) will be tested for the 
secondary endpoint. Confidence intervals will be presented with significance probability of the 
difference between the mean values.  
 
Data on other  secondary endpoints will be summarised descriptively.  
15.4 Analysis of Clinical Data 
The intent -to-treat (ITT) analysis population is define as all patient s enrolled in the study.  Patient s 
in this analysis population will be analyzed according to the group to which they were randomized. 
The per protocol (PP) analysis population is a subset of the ITT population and excludes those 
patient s with a protocol deviation  that could affect the measurement of the primary endpoint .  For 
example,  a patient  who uses over the counter products for dry mouth during the course of the study.  
 
Descriptive summaries will be produced for the primary endpoints and the secondary endpoin ts 
using data from the intent -to-treat analysis population.  
 
Hypothesis testing for the primary endpo ints will be carried out using data from the intent -to-treat 
analysis population and, as a sensitivity analysis, from the per protocol analysis population.  The 
change in VAS associated for each product will be estimated as the value of VAS at the end of a 
treatment period  minus the value of VAS before the first dose  in the same period . The difference 
in mean change in VAS for dry mouth between MucoPEG   and Biotène®  Dry Mouth Gentle 
Oral Rinse  will be tested in a Student’s t -test. Th e difference in the proportion of patients rating 
the relief of dry mouth as “ Very Good” or “ Significant / E xcellent” will be tested in a binomial 
test of difference between two p roportions . We will consider using statistical methods  that are 
more suitable for smaller sample sizes (for example: exact binomial  test, bootstrappi[INVESTIGATOR_007])  if they are 
applicable.  
 
16 SOURCE DOCUMENTS  
Study staff will maintain appropriate study records for this study, in compliance with GCP , 
and regulatory and institutional requirements for the protection of confidentiality  
of patient s. Study staff will permit authorized representatives the Sponsor and regulatory  
agencies to examine (and when required by [CONTACT_1289], to copy) research records for the  
purposes of quality assurance reviews, audits, and evaluation of the study safety, progress  
and data validity.  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_848] (IRB)  
Prior to the initiation of this clinica l investigation, the Principal I nvestigator must submit the 
Clinical Investigation Plan , the Informed Consent Form  and any other study documents , as 
required , to the appropriate IRB for revie w and approval.  The Principal I nvestigator, and any other 
member of the investigative team, must not participate in the IRB review of this clinical study .  A 
signed and dated letter granting approval must be provided to SunBio, Inc. or the designated CRO  
prior to the initiation of the clinical investigation .  A list of the voting members of the IRB 
reviewing this Clinical Investigation Plan may be requested.  
 
17.2 Informed Consent Process  
Informed consent is a process that is initiated prior to the patient ’s agreement to participate in the 
study and continues throughout the study participation. The Principal Investigator , or designee  
must explain to each patient the nature of the clinical investigation, including any risks and benefits, 
its purpose and proc edures, and expected duration of involvement in the clinical investigation.  
Each patient must be informed that participation in the clinical investigation is voluntary and non -
participation will not affect his / her right to the treatment the patient is e ntitled to receive or affect 
the doctor/clinician -patient relationship. Each patient must be given sufficient time to decide 
whether they wish to participate and have all their que stions  addressed prior to signing the IRB -
approved consent form(s). A copy o f the signed consent form(s) must be provided to the patient. 
Study specific procedures will not be initiated until the patient  has signed the appropriate consent 
forms(s). Patients have full rights to withdraw from the clinical investigation at any time, 
irrespective of their initial consent.  
 
Each patient  must also give their permission for representatives of the Sponsor, audit or and 
regulatory authorities to review their hospi[INVESTIGATOR_1248].  
 
Informed consent from the patient  must be obtained in writing before any clinical investigation 
related procedures are performed.  
17.3 Patient  Confide ntiality  
Confidentiality of patient  data will be maintained at all times and all documentation relating to a 
patient  will be kept in a secure location.  
 
Study participant’s research data will be transmitted to the sponsor. This will not include 
participant’s contact [CONTACT_1290]. Rather, samples will be de -identified using a study 
specific number at the time of enrollment.  All study forms wi ll be labeled with the study number. 
No identifiable patient information will be provided to the sponsor or CRO.  
 
Study  documents  provided  to the  sponsor will be stored  in a secure  location  with access  given to 
only those that require study access .  None  of the stored  documents  will contain  any personal  
identifying  information  or direct  identifiers. 
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 37 of 49 
 Study  files will be made  available  to the IRB,  regulatory  authorities,  Sponsor  (or designee)  
and/or  clinical  study  staff should  they request  access  for auditing  purposes.   
 
18 TERMINATION OF THE C LINICAL INVESTIGATIO N 
In case of a study close -out, the Investigators will be notified by [CONTACT_1291] . 
Appropriate notification/report to IRB will be provided, as required per 21CFR812 . After study 
close -out, the follow -up treatment and medical care of the patient s will continue to be as per routine 
practice of the site.  
18.[ADDRESS_849], documenting the 
reason for study suspension or termination, will be provided by [CONTACT_1292]. If the study is prematurely termina ted or suspended, the Principal I nvestigator will promptly 
inform the IRB/IEC and will provide the reason(s) for suspension or termination.  
 
Circumstances that may warrant termination include, but are not limited to:  
• Insufficient adherence to protocol requirements.  
• Data that are not sufficiently complete and/or evaluable.  
• Determination of futility  
 
19 DATA MANAGEMENT    
19.1 Data Collection Methods  
Electronic Case Report Forms (eCRFs) will be used to capture data for performance and safety 
analysis. The clinical database will reside on a production server hosted by [CONTACT_1293]. Instructions 
and training for use of the EDC system and proper completion of the form s will be provided to 
the clinical sites.  All changes made to the data will be in an electronic audit trail and available 
for review. The database will be subject to quality control checks according to the study specific 
Data Management Plan and NA MSA’s standard procedures.  
Data  collection  and accurate  documentation  are the responsibility  of the study  staff under  the 
supervision  of the investigator  or designee . Unanticipated  problems  must  be reviewed  by [CONTACT_1294].   
19.[ADDRESS_850] not received treatment, wil l not be used in the analysis. Details of 
these patients will, however,  be referenced in the final report.  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page [ADDRESS_851] received the investigational device /study product , who 
withdraw voluntarily or who are withdrawn from the clinical investigation, will be used in the final 
analysis.  The inclusio n of partial data will be documented in the final report. The final report will 
be the  responsibility of SunBio, Inc. or the designated CRO.  
19.[ADDRESS_852] 2 years  after the latter of the following  two dates:  the date on which  the 
study  is terminated  or completed,  or the date that the records  are no longer  required  for purposes  
of supporting  FDA  clearance  of the product and/or required by [CONTACT_1295] s. In all cases, the 
Principal I nvestigator must obtain written consent from the Sponsor prior to disposing of any 
records related to the clinical investigation.  Included in records to be maintained are signed 
Clinical Investigation Plan, copi[INVESTIGATOR_1249] s, signed consent forms, IRB approval 
letters, product accountability records, correspondence concerning the clinical study and any other 
documents to identify the patient s.  
 
In addition, if the Principal Investigator [INVESTIGATOR_1250]/retires, etc., s/he should provide the Sponsor  with 
the name [CONTACT_1302] /company that will be responsible for the clinical investigation 
related records.  
 
20 INVESTIGATOR/INVESTI GATION SITE SELECTIO N 
20.[ADDRESS_853] experience in the therapy being studied . 
20.2 Site Selection Criteria  
The following requirements will be evaluated for each investigation site considered for 
participation in the clinical study:  
 Past experience of site staff in conducting clinical studies  
 Adequate resources (including study nurse or coordinator), facilities and administrative 
support for the total study duration  
 Site has the capacity to recruit enough patient s for the study.  
 Computer with access to EDC system  
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 39 of 49 
 21 PUBLICATIONS AND COM MUNICATIONS  
21.1 Clinical Investigation Report  
The final report will be compi[INVESTIGATOR_1251], reviewed by [CONTACT_1296], Inc.  and reviewed, approved 
and signed off by [CONTACT_079].  
21.2 Publications  
Details of publications will be addressed  in each Clinical Trial  Agreement.  
 
22 MISCELLANEOUS  
22.1 Statement Regarding the Funding of the Study  
This Clinical Investigation is a 100% Sponsor funded Investigation.  
 
22.[ADDRESS_854], signed by [CONTACT_1297]. The investigator is indicating approval of the Cl inical Investigation Plan and subsequent 
amendments, by  a fully executed agreement. Amendments to this Clinical Investigation Plan shall 
be agreed upon between Sponsor and investigator(s) and be recorded with a justification for the 
amendments.  Furthermore , each Investigator(s) should provide signed Financial Disclosure Forms 
to disclose a Conflict of Interest.  
 
23 LITERATURE REFERENCE S 
 
Furness, S., Worthington, H. V., Bryan, G., Birchenough, S., & McMillan, R. (2011). 
Interventions for the management of dry mouth: topi[INVESTIGATOR_1252].  Cochrane Database of 
Systematic Reviews , (12).  
 
Jose, A., Siddiqi, M., Cronin, M., DiLauro, T. S., & Bosma, M. L. (2016). A randomized clinical 
trial in subjects with dry mouth evaluating subjective perceptions of an experimental oral gel, an 
oral rinse and a mouth spray compared to water.  American journal of dentistry , 29(1), 58 -64. 
 
Villa, A., Connell, C. L., & Abati, S. (2015). Diagnosis and management of xerostomia and 
hyposalivation.  Therapeutics and clinical risk management , 11, 45. 
 
Tan, E. C., Lexomboon, D., Sandborgh‐Englund, G., Haasum, Y., & Johnell, K. (2018). 
Medications that cause dry mouth as an adverse effect in older people: A systematic review and 
metaanalysis.  Journal of the American Geriatrics Society , 66(1), 76-84. 
 
Dawes, C. (1987). Physiological factors affecting salivary flow rate, oral sugar clearance, and the 
sensation of dry mouth in man.  Journal of dental research , 66(2_suppl), 648 -653. 
 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 40 of 49 
 Furuta, M., & Yamashita, Y. (2013). Oral health and swallowing problems.  Current physical 
medicine and rehabilitation reports , 1(4), 216 -222. 
 
Sheftel, V. O. (2000).  Indirect food additives and polymers: migration and toxicology . CRC 
Press.  
 
Shahdad, S. A., Taylor, C., Barclay, S. C., Steen, I. N., & Preshaw, P. M. (2005). A double‐
blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in 
patients with post‐radiotherapy xerostomia.  European journal of cancer care , 14(4), 319 -326. 
 
KRIS P. ANTONSEN and ALLAN S. HOFFMAN (1992) Water S tructure of PEG Solutions by 
[CONTACT_1298].  Poly(Ethylene Glycol) Chemistry/  
Biotechnical and Biomedical Applications, Chapter 2. 15 -28 
 
S Osailan et al “Investigating the relationship between hyposalivation and mucosal 
wetness“ (2011) Oral Diseases volume 17, Issue 1, Pages: 109 –114 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 41 of 49 
 APPENDIX A : VAS Questionnaire s 
Visual Analog ue Scale  
The Visual Analogue Scale questionnaire will be provided to the patient and the patient will be instructed 
to rate the dryness of their mouth and tongue  by [CONTACT_1299] a single mark on the line . 
 
1. Rate the dryness of your mouth  
 
      0        1        2        3        4        5        6        7        8        9       10  
Not dry at all             Very dry  
 
2. Rate the dryness of your tongue  
 
      0        1        2        3        4        5        6        7        8        9       10  
Not dry at all             Very dry  
 
  

Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 42 of 49 
 APPENDIX B: Dry Mouth Relief Questionnaire 
Dry Mouth Relief Questionnaire 
 
The Dry Mouth Relief Questionnaire is given to th e patient and they must answer the following  q
uestion: 
 
Does the product relieve the discomfort of dry mouth? 
 
Please check only one response:   
 None / (No relief) (1) 
 Not enough (2)  
 Some/Good (3) 
 Very Good (4)  
 Significant / Excellent (5)  
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 43 of 49 
 APPENDIX C: Dry Mouth Inventory Questionnaire 
Dry Mouth Inventory (DMI) 
 
The Dry Mouth Inventory questi onnaire is given to the patient and they must answer the             
following  question: 
  
Please check only one response to each of the following questions: 
 1. My mouth feels dry 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
2. I have difficulty in eating dry foods 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
3. I get up at night to drink 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
4. My mouth feels dry when eating a meal 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
5. I sip liquids to aid in swallowing food 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
6. I suck sweets or cough lollies to relieve dry mouth 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 44 of 49 
 7. My lips stick to the teeth 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
8. My tongue sticks to the roof of mouth 
 Disagree (0) 
 Agree a little (1) 
 Agree (2)  
 Strongly agree (3) 
 
 
 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 45 of 49 
 APPENDIX D: PPAQ & PPUQ Questionnaire 
The PPAQ (Product Performance and Attributes  Questionnaire) and PPUQ (Post-Product Use 
Questionnaire) are included below : 
 
PPAQ1: The PPAQ1 Questionnaire is given to the patient 5 (+ 5)  minutes after the product is 
administered. The patient must answer questions 1-3 below while in clinic. 
 
No. Question item Answer 
1 Relieving the discomfort of dry mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
2 Effectively moistens your mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
3 Effectively lubricates your mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
 
PPAQ2: The PPAQ2 Questionnaire is given to the patient 30 (± 10)  minutes after the product is 
administered. The patient must answer questions 1-11 below while in clinic.  
 
No. Question item Answer 
1 Relieving the discomfort of dry mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
2 Effectively moistens your mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
3 Effectively lubricates your mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
4 Feeling comfortable in the mouth  Poor (1) 
 Fair (2) 
 Good (3) 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 46 of 49 
  Very Good (4)  
 Excellent (5) 
5 Soothing your mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
6 Allowing you to speak without difficulty  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
7 Helpi[INVESTIGATOR_1253] (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
8 Protecting your mouth from drying out  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
9 Providing whole mouth comfort  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
10 Helpi[INVESTIGATOR_1254] (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
11 Helpi[INVESTIGATOR_1255] ‘normal’   Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
 
PPAQ3: The PPAQ3 Questionnaire is given to the patient at three (3) different timepoints (60,120 and 
240 minutes).  
The first one is given 60 (± 10)  minutes after the product is administered and must be completed in clinic.  
The second one is given to the patient 120 (± 10)  minutes after the product is administered and must be 
completed in clinic. The third one is given to the patient 240 (± 10)  minutes after the product is 
administered and must be completed in clinic or at home. For PPAQ3, the patient must answer questions 
12-14 below at each timepoint.  
 
No. Question item Answer 
12 Having a long-lasting dry mouth relief  Poor (1) 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 47 of 49 
  Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_855]  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_856]  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
 
 
PPAQ4: The PPAQ4 Questionnaire is only given to the patient at Visits 3, 4, [ADDRESS_857] be completed while the patient is in clinic.  
 
No. Question item Answer 
15 Providing relief all night  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
16 Reducing the number of times you wake up from 
dry mouth  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
17 Feeling less parched when you wake up  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
18 Having a long-lasting dry mouth relief  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_858]  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_859]  Poor (1) 
 Fair (2) 
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                            2021  
_____________________________________________________________________________________________   
 
 
NAMSA Template #: CSOP-005-T01 Sponsor: SunBio  Confidential     Page 48 of 49 
  Good (3) 
 Very Good (4)  
 Excellent (5) 
21 Having an overall dry mouth relief  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_860]  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
[ADDRESS_861]  Poor (1) 
 Fair (2) 
 Good (3) 
 Very Good (4)  
 Excellent (5) 
 
 PPUQ: 
The PPUQ Questionnaire is given to the pa tient only at Visits 4 and 7, 240 (± 10)  minutes after 
the product is administered. UThe patient must answer questi on [ADDRESS_862]?   Yes 
 No 
  
Clinical Evaluation of MucoPEG  for Xerostomia       1.1   
SB-MU-001                                                                          November  2021  
_____________________________________________________________________________ ________________   
 
 
NAMSA Template #: CSOP -005-T01 Sponsor: SunBio  Confidential      Page 49 of 49 
 APPENDIX E: The Challacombe Scale  
The Challacombe Scale  will be provided in a separate document.  The Principal Investigator [INVESTIGATOR_1256].  Per ( S Osailan et al, 2011) , the Challacombe Scale was developed 
from research conducted at King’s College London Dental Institute under the supervision o f [CONTACT_1303] . The purpose of this scale is to be able to visually identify and quantify whether 
your patient has xer ostomia (dry mouth) and if so, how it changes over time and the most appropriate 
therapy options. This scale is applicable whatever your profession. The Challacombe Scale works as an 
additive score of 1 to 10 : [ADDRESS_863] sever e. Each feature scores 1 and 
symptoms will not necessarily progress in the order shown, but summated scores indicate likely patient 
needs. Score changes over time can be used to monitor symptom progression or regression.  
 
The Challacombe Scale Score may in clude the following assessments:  
 
1. Mirror sticks to buccal mucosa  
2. Mirrors sticks to tongue  
3. Saliva frothy  An additive score of 1 - 3 indicates mild  
dryness. May not need treatment or  
management. Sugar -free chewing gum  
for 15 mins, twice daily and attention  
to hydration is needed. Many drugs will  
cause mild dryness. Routine checkup  
monitoring required.  
4. No saliva pooling in floor of mouth  
5. Tongue shows generalized shortened 
papi[INVESTIGATOR_1257] (mild depapi[INVESTIGATOR_1258])  
6. Altered gingival architecture (i.e. smooth)  An additive s core of 4 - 6 indicates  
moderate dryness. Sugar -free chewing  
gum or simple sialogogues may be  
required. Needs to be investigated further  
if reasons for dryness are not clear.  
Saliva substitutes and topi[INVESTIGATOR_1259]. Monitor at regular intervals  
especially for early decay and symptom  
change.  
7. Glassy appearance of oral mucosa, 
especially palate  
8. Tongue lobulated/fissured  
9. Cervical caries (more than two teeth)  
10. Debris on palate or sticking to teeth  An additive score of [ADDRESS_864] input if  
worsening.  
 
 
 
 
 
 
 
 
 
 
 
 